{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:16:16Z","timestamp":1788671776466,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020957","name":"Roche Germany Holding GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001009","name":"Bristol-Myers Squibb Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmorw.2025.100667","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T21:13:33Z","timestamp":1768425213000},"page":"100667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Final results of the INFINITY precision oncology registry: non-standard targeted treatments in patients with advanced cancers in routine care"],"prefix":"10.1016","volume":"11","author":[{"given":"L.","family":"Sellmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1639-8762","authenticated-orcid":false,"given":"D.","family":"Marschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.M.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0457-7793","authenticated-orcid":false,"given":"M.","family":"Reiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.K.","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vannier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Loo\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Woerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Grebhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.R.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0110-8585","authenticated-orcid":false,"given":"B.","family":"Kasenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Busies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1015-9624","authenticated-orcid":false,"given":"K.","family":"Potthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmorw.2025.100667_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: evolution of the treatment paradigm","volume":"86","author":"Tsimberidou","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.esmorw.2025.100667_bib2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3390\/jpm11030216","article-title":"Translational research in the era of precision medicine: where we are and where we will go","volume":"11","author":"De Maria Marchiano","year":"2021","journal-title":"J Pers Med"},{"issue":"1","key":"10.1016\/j.esmorw.2025.100667_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13073-019-0703-1","article-title":"Molecular profiling for precision cancer therapies","volume":"12","author":"Malone","year":"2020","journal-title":"Genome Med"},{"key":"10.1016\/j.esmorw.2025.100667_bib4","article-title":"Molecular profiling-based precision medicine in cancer: a review of current evidence and challenges","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.esmorw.2025.100667_bib5","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","article-title":"Cancer biomarkers - emerging trends and clinical implications for personalized treatment","volume":"187","author":"Passaro","year":"2024","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100667_bib6","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.esmorw.2025.100667_bib7","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jamaoncol.2016.2129","article-title":"Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis","volume":"2","author":"Schwaederle","year":"2016","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.esmorw.2025.100667_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-019-0835-1","article-title":"Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine","volume":"12","author":"Tsimberidou","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"15","key":"10.1016\/j.esmorw.2025.100667_bib9","doi-asserted-by":"crossref","first-page":"12316","DOI":"10.18632\/oncotarget.24384","article-title":"Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs","volume":"9","author":"Haslem","year":"2018","journal-title":"Oncotarget"},{"issue":"10452","key":"10.1016\/j.esmorw.2025.100667_bib10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(24)00814-6","article-title":"Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study","volume":"404","author":"Kr\u00e4mer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.esmorw.2025.100667_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2019.100493","article-title":"Biomarker-guided trials: challenges in practice","volume":"16","author":"Antoniou","year":"2019","journal-title":"Contemp Clin Trials Commun"},{"issue":"11","key":"10.1016\/j.esmorw.2025.100667_bib12","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmorw.2025.100667_bib13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/jcpt.12507","article-title":"Off-label drug use in oncology: a systematic review of literature","volume":"42","author":"Saiyed","year":"2017","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"10.1016\/j.esmorw.2025.100667_bib14","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","article-title":"Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial","volume":"25","author":"Rodon","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.esmorw.2025.100667_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00122","article-title":"Rationale and design of the Targeted Agent and Profiling Utilization Registry (TAPUR) study","volume":"2","author":"Mangat","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100667_bib16","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","article-title":"The NCI-MATCH trial: lessons for precision oncology","volume":"29","author":"O\u2019Dwyer","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.esmorw.2025.100667_bib17","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/j.clon.2019.05.003","article-title":"Generalisability of common oncology clinical trial eligibility criteria in the real world","volume":"31","author":"Karim","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.esmorw.2025.100667_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113323","article-title":"Precision oncology medicines and the need for real world evidence acceptance in health technology assessment: importance of patient involvement in sustainable healthcare","volume":"193","author":"Geissler","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmorw.2025.100667_bib19","article-title":"An approach to solving the complex clinicogenomic data landscape in precision oncology: learnings from the design of WAYFIND-R, a global precision oncology registry","volume":"6","author":"Le Tourneau","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.esmorw.2025.100667_bib20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1186\/s12885-023-11046-3","article-title":"The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice","volume":"23","author":"Martens","year":"2023","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.esmorw.2025.100667_bib21","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO Guidance for Reporting Oncology real-World evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"},{"issue":"33","key":"10.1016\/j.esmorw.2025.100667_bib22","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","article-title":"Pilot study using molecular profiling of patients\u2019 tumors to find potential targets and select treatments for their refractory cancers","volume":"28","author":"Von Hoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmorw.2025.100667_bib23","series-title":"R: A Language and Environment for Statistical Computing","year":"2021"},{"key":"10.1016\/j.esmorw.2025.100667_bib24","article-title":"Real-world outcomes of molecular tumor board treatment recommendations","volume":"9","author":"Nichetti","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmorw.2025.100667_bib25","article-title":"Off-label drug use in oncology: integrating molecular and genetic analysis in an academic center\u2019s real-world approach","volume":"7","author":"Cioli","year":"2025","journal-title":"ESMO Real World Data Digit Oncol"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100667_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100637","article-title":"COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy","volume":"7","author":"Pixberg","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmorw.2025.100667_bib29","doi-asserted-by":"crossref","DOI":"10.2340\/1651-226X.2023.33322","article-title":"Pioneering the implementation of a precision oncology strategy in Portugal: the Precision Oncology Platform trial","volume":"63","author":"Mainoli","year":"2024","journal-title":"Acta Oncol"},{"issue":"7776","key":"10.1016\/j.esmorw.2025.100667_bib30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-019-1600-x","article-title":"The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs","volume":"574","author":"van der Velden","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.esmorw.2025.100667_bib31","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.11515","article-title":"SHIVA: randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer\u2014overall survival (OS) analysis","volume":"35","author":"Dureau","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmorw.2025.100667_bib32","article-title":"Molecular-guided off-label targeted therapy in a large-scale precision oncology program","volume":"7","author":"Vashistha","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"10.1016\/j.esmorw.2025.100667_bib33","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1158\/2159-8290.CD-21-0126","article-title":"Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers","volume":"11","author":"Horak","year":"2021","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.esmorw.2025.100667_bib34","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/PO.20.00248","article-title":"CATCH: a prospective precision oncology trial in metastatic breast cancer","author":"Hlevnjak","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.esmorw.2025.100667_bib35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E\u2013mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmorw.2025.100667_bib36","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1001\/jama.2016.19970","article-title":"Using design thinking to differentiate useful from misleading evidence in observational research","volume":"317","author":"Goodman","year":"2017","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.esmorw.2025.100667_bib37","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/2159-8290.CD-21-0094","article-title":"The pediatric precision oncology INFORM registry: clinical outcome and benefit for patients with very high-evidence targets","volume":"11","author":"van Tilburg","year":"2021","journal-title":"Cancer Discov"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820125005569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820125005569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:53:40Z","timestamp":1788670420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820125005569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"alternative-id":["S2949820125005569"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2025.100667","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Final results of the INFINITY precision oncology registry: non-standard targeted treatments in patients with advanced cancers in routine care","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2025.100667","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100667"}}